Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22050825 | 0.89 | MAPT (0.50) | L3MBTL1ALDH1A1GAAPOLBMEN1 | |
| SCHEMBL21749673 | 0.88 | ALDH1A1 (0.50) | L3MBTL1ALDH1A1GAAPOLBMEN1 | |
| SCHEMBL21749680 | 0.86 | ALDH1A1 (0.48) | L3MBTL1ALDH1A1GAAMEN1KMT2A | |
| SCHEMBL22050842 | 0.86 | ALDH1A1 (0.52) | ALDH1A1GAAKMT2ASMN1; SMN2HTT | |
| SCHEMBL18038951 | 0.82 | L3MBTL1 (0.52) | L3MBTL1ALDH1A1GAAPOLBSMN1; SMN2 | |
| SCHEMBL18038979 | 0.82 | L3MBTL1 (0.52) | L3MBTL1ALDH1A1GAAPOLBSMN1; SMN2 | |
| SCHEMBL18038965 | 0.82 | L3MBTL1 (0.52) | L3MBTL1ALDH1A1GAATP53POLB | |
| SCHEMBL18038959 | 0.82 | L3MBTL1 (0.56) | L3MBTL1ALDH1A1GAATP53POLB | |
| SCHEMBL18038989 | 0.82 | L3MBTL1 (0.56) | L3MBTL1ALDH1A1GAATP53POLB | |
| SCHEMBL18038954 | 0.82 | L3MBTL1 (0.56) | L3MBTL1ALDH1A1GAATP53POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11311523-B2 | Pyridinone compound and use thereof | KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (JP) | 2022-04-26 | — | — | US | disclosed |
| US-20200061039-A1 | PYRIDINONE COMPOUND AND USE THEREOF | KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (JP) | 2020-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200061039-A1 | PYRIDINONE COMPOUND AND USE THEREOF | DOCK5, DOCK2, CIB1 | L3MBTL1 2940/4885ALDH1A1 49/4885GAA 4691/4885 |
| US-11311523-B2 | Pyridinone compound and use thereof | DOCK5, DOCK2, CIB1 | L3MBTL1 2940/4885ALDH1A1 49/4885GAA 4691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.